References: Vancomycin monitoring and dosage adjustment in adults

  • Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004;38(3):448-51. https://www.ncbi.nlm.nih.gov/pubmed/14727222
  • Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ. Establishment of an AUC(0-24) Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 2017;61(5). https://www.ncbi.nlm.nih.gov/pubmed/28242672
  • Chen M, Lee C, Gnyra M, Wong M. Vancomycin area under the curve/minimum inhibitory concentration and trough level concordance-evaluation on an urban health unit. Ther Adv Infect Dis 2022;9:20499361221140368. https://www.ncbi.nlm.nih.gov/pubmed/36465428
  • Chuma M, Hamano H, Bando T, Kondo M, Okada N, Izumi Y, et al. Non-recovery of vancomycin-associated nephrotoxicity is related to worsening survival outcomes: Combined retrospective analyses of two real-world databases. Basic Clin Pharmacol Toxicol 2022;131(6):525-35. https://www.ncbi.nlm.nih.gov/pubmed/36169161
  • Covvey JR, Erickson O, Fiumara D, Mazzei K, Moszczenski Z, Slipak K, et al. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia. Ann Pharmacother 2020;54(7):644-51. https://www.ncbi.nlm.nih.gov/pubmed/31888350
  • D’Amico H, Wallace KL, Burgess D, Burgess DS, Cotner S, Mynatt R, et al. Acute Kidney Injury Associated with Area under the Curve versus Trough Monitoring of Vancomycin in Obese Patients. Antimicrob Agents Chemother 2022;66(1):e0088621. https://www.ncbi.nlm.nih.gov/pubmed/34633843
  • Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, et al. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. Antimicrob Agents Chemother 2017;61(12). https://www.ncbi.nlm.nih.gov/pubmed/28923869
  • Haag H, Lau A. Correlation of Calculated Vancomycin Trough Concentrations and Exposure: A Monte Carlo Simulation. Ann Pharmacother 2023:10600280231160571. https://www.ncbi.nlm.nih.gov/pubmed/36999486
  • Mahmoud SH, Shen C. Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing. Pharmaceutics 2017;9(3). https://www.ncbi.nlm.nih.gov/pubmed/28926966
  • Martirosov DM, Bidell MR, Pai MP, Scheetz MH, Rosenkranz SL, Faragon C, et al. Relationship between day 1 and day 2 vancomycin area under the curve values and emergence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest(R) macromethod among patients with MRSA bloodstream infections: a pilot study. BMC Infect Dis 2017;17(1):534. http://www.ncbi.nlm.nih.gov/pubmed/28764660
  • Neely MN, Kato L, Youn G, Kraler L, Bayard D, van Guilder M, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother 2018;62(2). https://www.ncbi.nlm.nih.gov/pubmed/29203493
  • Pai MP, Hong J, Krop L. Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers Bias. Antimicrob Agents Chemother 2017;61(4). https://www.ncbi.nlm.nih.gov/pubmed/28096158
  • Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020;77(11):835-64. https://www.ncbi.nlm.nih.gov/pubmed/32191793
  • Uster DW, Wicha SG. Optimized sampling to estimate vancomycin drug exposure: Comparison of pharmacometric and equation-based approaches in a simulation-estimation study. CPT Pharmacometrics Syst Pharmacol 2022;11(6):711-20. https://www.ncbi.nlm.nih.gov/pubmed/35259285